Menu
Scroll to Top
Lilium is developing novel Synthetic Targeted (STAR) Vectors for systemic gene delivery, addressing the inefficiencies of current viral and non-viral delivery vehicles. Their innovative approach allows for precise targeting, high tissue tropism, low immunogenicity, and larger payloads, enabling treatment for millions of patients with prevalent and untreatable diseases across various therapeutic areas. This positions Lilium as a leader in the gene therapy market, aiming to make advanced treatments accessible to a broader population.
Something looks off?